A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Clinical trial NCT06369285 · RECRUITING

Trial details

NCT number: NCT06369285
Sponsor: Puma Biotechnology, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hormone Receptor Positive HER-2 Negative Breast Cancer Metastatic Breast Cancer Recurrent Breast Cancer

Start date: 2024-11-19
Primary completion: 2027-12-30
Enrollment: 225

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.